Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

with a focus on expanding access to Gilead’s therapies and driving sustainable growth. Petrelli has experience in the ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $ ...

The firm decreased its portfolio allocation in GILD by 9.71% over the last quarter. Gilead Sciences Background Information ...

Gilead is with­draw­ing the ac­cel­er­at­ed ap­proval for its block­buster an­ti­body-drug con­ju­gate Trodelvy for blad­der can­cer af­ter it failed to im­prove sur­vival odds ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

Gilead Sciences plans to voluntarily withdraw U.S. accelerated approval for Trodelvy in metastatic urothelial cancer. The decision followed results from the TROPiCS-04 study, which failed to meet ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...